glycine and tirzepatide microdose compounded Microdosing Tirzepatide + Product – 2ML Tirzepatide + Glycine +

1 Consider treatment response and tolerability when selecting the maintenance dosage 1 Recommended maintenance doses: Adult CV risk reduction: 1.7 mg or 2.4 mg (recommended) Adult weight reduction: 1.7 mg, 2.4 mg (recommended), or 7.2 mg (when additional weight reduction is clinically indicated) Adolescent weight reduction: 1.7 mg or 2.4 mg (recommended) CV, cardiovascular

The only authoritative source is your clinical trial protocol, study sponsor, or dispensing pharmacy there is no NHS or NICE guidance available for this compound

Similarly, the CONQUER trial found that people on mid and maximum doses lost around 7% and 9% more weight, respectively, than the placebo group

Labeling Review: Prescribing information and warnings

Some people experience slight weight changes